Health-related quality of life among transthyretin amyloid cardiomyopathy patients.
ATTR CM
Amyloidosis
Cardiomyopathy
Observational study
Patient-reported outcome measures
Quality of life
Transthyretin
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
22
02
2023
received:
17
11
2022
accepted:
26
02
2023
medline:
19
5
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health-related quality of life (HRQoL) in ATTR CM patients. The Nordic PROACT study was a cross-sectional non-interventional study conducted in 12 cardiology hospital clinics across Norway, Sweden, Finland and Denmark. Men and women aged ≥18 years diagnosed with symptomatic ATTR CM were included. The investigator provided information on medical history, biomarkers, current treatment, co-morbidities and disease severity according to the New York Heart Association (NYHA) class and the National Amyloidosis Centre (NAC) staging. Patients completed the HRQoL questionnaires in the form of the Kansas City Cardiomyopathy Questionnaire (KCCQ), the EQ-5D-5L index with Visual Analog Scale (VAS), and the Major Depression Inventory (MDI). A total of 169 patients (mean ± SD age 77.7 ± 6.2 years) were included. Ninety-two per cent were men. Seventy-six per cent had wildtype ATTR CM (ATTRwt CM) and 15% had a hereditary form of ATTR CM (ATTRv CM) while 9% were genetically unclassified. Most patients were in NYHA class II (54%) and NAC stage 1 (53%). Participation in randomized clinical trials (RCT) was noted in 58% of the patients. The 169 ATTR CM patients had a mean ± SD KCCQ score of 64.3 ± 23.1 for total symptom score, 64.8 ± 20.9 for overall summary score (OSS) and 65.1 ± 21.5 for clinical summary score. The EQ-5D-5L total utility score was 0.8 ± 0.2 and the EQ-5D-5L VAS score was 62.9 ± 20.6. The vast majority (89%) did not report any signs of depression. Patients with ATTRv CM had a higher KCCQ OSS as compared with ATTRwt CM, while EQ-5D-5L utility score, EQ-5D-5L VAS and MDI were similar. Non-RCT participants had a poorer HRQoL as compared with RCT participants as reflected in lower KCCQ OSS and EQ-5D-5L VAS scores and a higher MDI score. Patients with higher NYHA classes and NAC disease stages had a poorer HRQoL as demonstrated by lower KCCQ and EQ-5D-5L scores and higher MDI scores. Correlation between KCCQ, EQ-5D-5L and MDI and the covariate NYHA class remained significant (P < 0.05) after adjusting for multiple testing. KCCQ scores were lower than previously reported for patients with other heart diseases of non-ATTR CM origin. The HRQoL measures correlated well to NYHA class and NAC disease stage. The prevalence of depression appeared to be low.
Identifiants
pubmed: 36946241
doi: 10.1002/ehf2.14350
pmc: PMC10192258
doi:
Substances chimiques
Prealbumin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1871-1882Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
J Am Coll Cardiol. 2000 Apr;35(5):1245-55
pubmed: 10758967
Nat Rev Cardiol. 2010 Jul;7(7):398-408
pubmed: 20479782
Qual Life Res. 2022 Feb;31(2):517-526
pubmed: 34272631
Amyloid. 2018 Sep;25(3):174-179
pubmed: 30169971
J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891
pubmed: 31171094
Eur J Heart Fail. 2021 Jun;23(6):895-905
pubmed: 33915002
Cardiovasc Drugs Ther. 2020 Jun;34(3):357-370
pubmed: 32062791
BMJ Open. 2021 Dec 3;11(12):e053216
pubmed: 34862295
Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):577-587
pubmed: 34244745
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
Neurol Ther. 2018 Dec;7(2):349-364
pubmed: 30073497
Qual Life Res. 2022 Mar;31(3):697-712
pubmed: 34628587
Annu Rev Med. 2020 Jan 27;71:203-219
pubmed: 31986086
Open Heart. 2021 Oct;8(2):
pubmed: 34645699
Am J Cardiol. 2021 Feb 15;141:98-105
pubmed: 33220323
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Amyloid. 2022 Sep;29(3):165-174
pubmed: 35144512
Eur Heart J. 2015 Oct 7;36(38):2585-94
pubmed: 26224076
J Med Econ. 2022 Jan-Dec;25(1):51-58
pubmed: 34907813
J Am Coll Cardiol. 2021 Dec 21;78(25):2505-2517
pubmed: 34915981
Circulation. 2012 Sep 4;126(10):1286-300
pubmed: 22949539
ESC Heart Fail. 2023 Jun;10(3):1871-1882
pubmed: 36946241
Amyloid. 2020 Sep;27(3):153-162
pubmed: 32131641
Int J Cardiol. 2020 Apr 1;304:138-143
pubmed: 32033783
Future Cardiol. 2022 Mar;18(3):165-172
pubmed: 34779246
ESC Heart Fail. 2022 Jun;9(3):1524-1541
pubmed: 35343098
Health Qual Life Outcomes. 2020 Oct 30;18(1):351
pubmed: 33126893
Circ Heart Fail. 2017 Aug;10(8):
pubmed: 28784687
Curr Med Res Opin. 2013 Jan;29(1):63-76
pubmed: 23193944
Clin Res Cardiol. 2021 Apr;110(4):479-506
pubmed: 33459839
ESC Heart Fail. 2022 Aug;9(4):2528-2537
pubmed: 35560802
Scand J Public Health. 2023 Mar;51(2):241-249
pubmed: 34847818
Eur Heart J. 2019 Apr 01;:
pubmed: 30938420
Circulation. 2019 Jul 2;140(1):16-26
pubmed: 31109193
Cardiol Ther. 2021 Jun;10(1):141-159
pubmed: 33877591
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
J Psychosom Res. 2017 Mar;94:1-9
pubmed: 28183396
Acta Cardiol Sin. 2016 Jan;32(1):55-61
pubmed: 27122931
Eur J Heart Fail. 2020 Nov;22(11):2007-2017
pubmed: 32468714
J Am Heart Assoc. 2020 Sep;9(17):e017278
pubmed: 32812460
Am J Cardiol. 2009 May 1;103(9):1285-9
pubmed: 19406273
Clin Epidemiol. 2017 Jul 06;9:355-365
pubmed: 28740432
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
Psychol Med. 2003 Feb;33(2):351-6
pubmed: 12622314
JACC Heart Fail. 2019 Oct;7(10):862-874
pubmed: 31302043